Iowa Neurological Association Annual Meeting
If you have questions, please contact Michelle Decker at MDekker@iowamedical.org or 515-421-4778.
Open to all interested health professionals.
Neurologists need to have and understand current delivery methods and treatment options for their patients. This conference will increase the knowledge of learners in multiple disease factors and delivery methods to improve the quality of care being given to their patients.
- Discuss how telemedicine technology may be use in the neurological practice.
- Explore issues related to advancing mind and brain health care across the region.
- Illustrate how to build an internet-based registry and database (RdB)
- Apply outreach, tracking, and evaluation approaches to partner with key practice sites to develop a RBRN (e.g., for Alzheimer’s Disease)
- Discuss issues related to data specification alignment, creation of software and informatics infrastructure to support registry toolsets, and informatics networks integration with additional health data applications, EHR platforms and biorepositories.
- Appreciate the advantages linking community members, practitioners, and researchers to build regional platforms for recruiting potential research subjects with neurological disorders.
- Explore the use of CGRP Antagonists in the managing patients with migraines.
- Outline the current American Board of Psychiatry and Neurology (ABPN) Maintenance of Certification (MOC) Program.
- Discuss the challenges of treating neurological patients infected with HIV and other infectious diseases.
- Describe the outcomes of a multi-specialty, multi-disciplinary, quality improvement project to improve stroke care and team communication.
- Discuss two case studies of anti-MOG associated demyelination with different clinical presentations.
- Review literature regarding anti-MOG and its treatment.
|7 am||Registration, Continental Breakfast and Exhibits|
Telemedicine in Neurology
Practice Based Research Networks for Clinical and Translational Research
CGRP Inhibitors for Migraine: Giant Leap or Step Forward
|11:30 am||Lunch and Business Meeting|
ABPN Current MOC Programs
Viruses and Fungi and Prions, Oh, My! Infectious Disease for the Neurologist
Resident Lecture: Acute Stroke Action Plan - A Joint Quality Improvement Project with UIHC ED
Resident Lecture: Anti- Myelin Oligodendrocyte Glycoprotein (MOG) Associated Demyelination
The education sessions offered today were planned without the influence of commercial interests. Lynne Rankin, MD has disclosed she is a PI for Amgen STRIVE and Alder PROMISE 2 phase 3 trials of CGRP antagonists for migraine prevention, received an honoraria from Allergan as preceptor for Botox for CM injection training, and future speaker for Teva and Eli Lilly.; however, all others involved in the planning and content development of this activity have no relevant financial relationships to report.
Continuing Education Credit
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University (DMU) and the Iowa Neurological Association. DMU is accredited by IMS to provide continuing medical education for physicians. DMU designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 6.25 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 6.25 continuing education contact hour(s). No partial credit awarded.
- Other Health Professional: This live activity is designated for 6.25 AMA PRA Category 1 Credit(s)TM.
No commercial interest company provided financial support for this continuing education activity.
Everyone in a position to control the content of this educational activity will disclose to the CME provider and to attendees all relevant financial relationships with any commercial interest. They will also disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director. Firms providing financial support did not have input in these areas. The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
- 6.25 AOA Category 2A
- 6.25 AMA PRA Category 1 Credits™
- 6.25 IBON
- 6.25 CE Contact Hour(s)